title: Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin.
abstract: OBJECTIVE
  The therapy with intravesical instillation of bacillus Calmette-Guérin (BCG) after transurethral resection (ITJR) of the tumor is the gold standard of treatment of non-muscle invasive bladder cancer (NMIBC). The aim of this study was to compare the frequencies of reccurence between a group of patients submitted to TUR + BCG therapy (group I) and a group of patients submitted only to TUR (group II).
  
  
  METHODS
  The patients with NMIBC, a total of 899, treated in our Institution from January 1, 2007 to March, 2013, were included in this study and divided into two groups: group I and group II. These two groups were divided into three subgroups: solitary first diagnosed tumor ≤ 3 cm (SFDGT), solitary first diagnosed tumor > 3 cm and multiple first diagnosed tumors (MFDGT), and recedive tumors (RCT). Statistical analysis was performed by using χ2-test and Kolmogorov-Smirnov test.
  
  
  RESULTS
  In the group I a total of 133 cases had reccurence contrary to 75 in the group II, making a statistically highly significant difference. Analysis of recurrences through the subgroups revealed: in the group I SFDGT recurrence occured in 27 of the cases vs 9 cases in the group II; in the group I MFDGT recurrence occured in 49 of the cases vs 31 in the group II (p < 0.001), and finally, in the group I RCT recurrence occured in 57 cases vs 35 cases in the group II (p < 0.001).
  
  
  CONCLUSIONS
  The obtained results indicate no difference in the frequency of reccurence between the group I and group II regarding SFDGT, but a very high significant difference regarding those with MFDGT and RCT. These results should be taken into consideration in everyday clinical practise.
authors.forename: Radovan
authors.initials: R
authors.lastname: Milošević
authors.forename: Novak
authors.initials: N
authors.lastname: Milović
authors.forename: Predrag
authors.initials: P
authors.lastname: Aleksić
authors.forename: Miodrag
authors.initials: M
authors.lastname: Lazić
authors.forename: Snežana
authors.initials: S
authors.lastname: Cerović
authors.forename: Vladimir
authors.initials: V
authors.lastname: Bančević
authors.forename: Branko
authors.initials: B
authors.lastname: Košević
authors.forename: Predrag
authors.initials: P
authors.lastname: Marić
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Spasić
authors.forename: Dejan
authors.initials: D
authors.lastname: Simić
authors.forename: Božidar
authors.initials: B
authors.lastname: Kovačević
mesh_terms: D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D055771:Serbia / Q000453:epidemiology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D001500:BCG Vaccine